Seçilmiş Gelişmekte Olan Ülkelerde Elektrik Tüketiminin Ekonomik Büyümeye Etkisinin Panel Ekonometrik Analizi

Nüfus artışı ve sanayi üretimindeki gelişmelere bağlı olarak, enerji tüketimi ile enerji tüketimi içerisindeki elektrik enerjisinin tüketimi de artmaktadır. Çoğu ülkenin elektrik enerjisi kullanımında dış dünyaya bağımlı olması, enerjiye stratejik bir ürün statüsü kazandırmakta ve hem politika yapıcılar hem de araştırmacılar için elektrik tüketimi ve ekonomik büyüme tartışmaları güncelliğini korumaktadır. Ülke grupları ve ülke örnekleri üzerine yapılan çok sayıdaki çalışmada, elektrik enerjisi tüketimi ile ekonomik büyüme arasındaki ilişki birbirinden farklı değişkenler yardımıyla araştırılmaktadır. Bütün bu literatürdeki ortak sonuç ise, enerjiyi verimli kullanan ülkelerde ekonomik büyümenin olumlu etkilendiği şeklindedir. Bu çalışmada, 1970-2014 dönemi verileriyle gelişmekte olan bazı ekonomiler için, ekonomik büyüme modeli elektrik enerjisi tüketiminin yanı sıra, ihracat ve karbondioksit emisyonu değişkenlerini de kullanarak yeni nesil ekonometrik yöntemler aracılığıyla tahmin yapılmaktadır. Ampirik sonuçlar, elektrik enerjisi tüketiminin ekonomik büyümeyi olumlu etkilediğini ortaya koymakta ve büyüme amacına yönelik olarak elektrik arzını arttırıcı politikaların desteklenmesi gerektiğini vurgulamaktadır

Factor XIII Val34Leu polymorphism in patients with cardiac syndrome X

Background: The aim of the study was to examine the frequency of factor XIII polymorphism among patients with cardiac syndrome X (CSX).Methods: This study was designed as a cross-sectional and observational study. Forty-eight female patients with CSX and 36 controls matched by age, gender, diabetes, and hypertension were studied. CSX was defined as typical chest pain during rest or effort, abnormal test result for exercise ECG, and presence of angiographically normal epicardial coronary arteries after ruling out inducible spasm. Factor XIII gene polymorphism was investigated by using CVD Strip Assay (ViennaLab Diagnostic GmbH) commercial kit.Results: The frequency of factor XIII (Val/Leu + Leu/Leu) mutation was significantly higher in patients with CSX (43%) than in controls (19%) (p = 0.02). Frequency of the Leu allele was significantly higher in the patient group (23.5% vs. 11.1%, p = 0.04). Factor XIII (Val/Leu + Leu/Leu) mutation (p = 0.01, OR = 3.42; 95% CI 1.22–9.58) and smoking (p = 0.04, OR = 3.33, 95% CI 1.05–10.58) were identified as independent predictors of the disease in multivariate regression analysis.Conclusions: This study indicates that there is an evidence for association between factor XIII Val34Leu polymorphism and CSX

Acute myocarditis or the kounis syndrome: Role of cardiac MRI and speckle-tracking echocardiography in diagnosis

Introduction: The Kounis syndrome and acute myocarditis are two distinct clinical entities, which could share nearly the same symptomatology as well as ECG (electrocardiography) and laboratory findings. Case Presentation: First case was a 39-year-old male presented with acute chest pain and inferolateral ST elevation on ECG. The second case was a 29-year-old male presented with chest pain and diffuses ST elevation. Diagnosis of acute myocarditis was achieved by demonstrating subepicardial contrast enhancement as well as atypical involvement in both of our clinical cases. Conclusions: We reported two cases in which specific imaging modalities (cardiac magnetic resonance imaging and speckle-tracking echocardiography) were used when the signs and symptoms were indistinguishable

Peripartum cardiomyopathy: Current state of knowledge, new developments and future directions

Peripartum cardiomyopathy (PPCM) is a form of idiopathic dilated cardiomyopathy affecting women in late pregnancy or early puerperium. Although initially described in the late 1800s, it has only recently been recognized as a distinct cardiac condition. The reported incidence and prognosis varies according to geography. The clinical course varies between complete recovery to rapid progression to chronic heart failure, heart transplantation or death. In spite of significant improvements in understanding the pathophysiology and management of the PPCM many features of this unique disease are poorly understood, including incidence, etiology, epidemiology, pathophysiology, predictors of prognosis and optimal therapy. The present article revisits these concepts and recent advances in PPCM

İnatçı koroner perforasyon olgusunda iç içe kaplı stent kullanımı

A sixty-four year old man with a previous history of CABG was referred for coronary angiography that revealed a critical stenosis of the right posterior descending artery at the anastomosis point of the saphenous vein graft (Figure A). Percutaneous intervention was initiated by engagement of the saphenous graft ostium with a 6F JR guiding catheter, followed by crossing the lesion with a hydrophilic guidewire. A drug-eluting stent, 2.25 x 23 mm in size, (Xience, Abbott Vascular, USA) was implanted at 14 atm pressure. Control angiography revealed a marked Ellis type IV coronary perforation with leakage of blood into the pericardial cavity (Figure B). Subsequently, the patient deteriorated hemodynamically with severe chest pain and hypotension. Echocardiography showed a marked pericardial effusion along with right ventricular collapse. Protamine sulfate was used to reverse anticoagulation followed by administration of IV fl uids and emergency pericardiocentesis. A 2.5 x 15 mm balloon (Sprinter Legend, Medtronic, USA) was advanced for 10 minutes of prolonged infl ation, which failed to heal the perforation (Figure C). A 2.80 x 19 mm covered stent (Graftmaster, Abbott Vascular, USA) was implanted at the level of the perforation

Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study

We congratulate the authors of the paper titled “Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study”, which evaluated 2242 consecutive patients with at least one atrial fibrillation (AF) in 17 different tertiary health care centers.[1] However, we have a few concerns about the study: 1. The efficacy and safety of warfarin anticoagulation in patients with AF are dependent on the intensity of anticoagulation measured as the international normalized ratio (INR). The risk of ischemic stroke increases with INR levels 3.5.[2] These findings support the standard “therapeutic” INR range for AF of 2.0-3.0. A commonly used summary of the quality of warfarin anticoagulation is the linearly interpolated percent time in the therapeutic range (TTR). TTR must be >65% for a better anticoagulation.[3] According to the report from the ACTIVE W trial, if the TTR

Factor XIII Val34Leu polymorphism in patients with cardiac syndrome X

WOS: 000334851000002PubMed ID: 23677728Background: The aim of the study was to examine the frequency of factor XIII polymorphism among patients with cardiac syndrome X (CSX). Methods: This study was designed as a cross-sectional and observational study. Forty-eight female patients with CSX and 36 controls matched by age, gender, diabetes, and hypertension were studied. CSX was defined as typical chest pain during rest or effort, abnormal test result for exercise ECG, and presence of angiographically normal epicardial coronary arteries after ruling out inducible spasm. Factor XIII gene polymorphism was investigated by using CVD Strip Assay (ViennaLab Diagnostic GmbH) commercial kit. Results: The frequency of factor XIII (Val/Leu + Leu/Leu) mutation was significantly higher in patients with CSX (43%) than in controls (19%) (p = 0.02). Frequency of the Leu allele was significantly higher in the patient group (23.5% vs. 11.1%, p = 0.04). Factor XIII (Val//Leu + Leu/Leu) mutation (p = 0.01, OR = 3.42; 95% CI 1.22-9.58) and smoking (p = 0.04, OR = 3.33, 95% CI 1.05-10.58) were identified as independent predictors of the disease in multivariate regression analysis. Conclusions: This study indicates that there is an evidence for association between factor XIII Val34Leu polymorphism and CSX